New tool aims to improve measurement
of primary care depression outcomes
Primary care doctors have long been on the front
lines of depression treatment. Depression is listed as a diagnosis for 1 in 10
office visits and primary care doctors prescribe more than half of all antidepressants.
Now doctors at the University of Michigan Health System have developed a new tool
that may help family physicians better evaluate the extent to which a patient's
depression has improved. The issue, the researchers explain, is that the
official definition of when a patient's symptoms are in remission doesn't always
match up with what doctors see in a real-world practice, especially for patients
with mild to moderate symptoms. The study will be published in the upcoming issue
of General Hospital Psychiatry. "Rather than simply going down a list
and checking off a patient's lack of individual symptoms, we believe there are
also positive signs that are important ? a patient's feeling that they are returning
to 'normal,' their sense of well-being, their satisfaction with life and their
ability to cope with life's ups and downs," says lead author Donald E. Nease
Jr., M.D., who was an associate professor of family medicine at the U-M Medical
School and member of the U-M Depression Center at the time of the research. Nease
and his colleagues developed a series of five questions - such as, "Over
the last two weeks, did you feel in control of your emotions?" - that they
hope will help doctors better understand a patient's inner landscape. The
remission criteria spelled out in the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) doesn't necessarily correspond to a patient's own sense of
recovery, Nease explains. For example, a patient could meet all the criteria for
full remission, but still not feel that he had recovered. The U-M questionnaire,
which is called Remission Evaluation and Mood Inventory Tool, or REMIT, is intended
to add the patient's subjective sense of recovery into the equation. Rather
than a replacement for current tools and measurements, REMIT is intended to compliment
them, say Nease, who is currently an adjunct professor at U-M. The researchers
used the REMIT tool alongside the current "gold standard" for monitoring
people with depression, the Patient Health Questionnaire (PHQ), Nease explains. The
data showed that by adding in the REMIT questions, about one-third of patients
with mild depression were not in remission, as their PHQ score would indicate.
Additionally, about one-third of moderately depressed patients were doing better
than their PHQ scores alone would denote. "Using just the PHQ score
across our study population, we saw about 60 percent accuracy in reflecting a
patient's remission compared to the patient's sense of his or her own recovery,"
Nease says. "If you add in the REMIT questions, we get above 70 percent.
This can give doctors new insights when making treatment choices, such as changing
a patient's medication or dosage." The current research looked at a
single snapshot in time for nearly 1,000 patients. The next step will be to track
patients' scores over time. Unlike other tools that require a company's
permission to use, the REMIT tool is available to any doctor who wants to use
it, Nease says. Additional authors are James E. Aikens, Ph.D., Michael S.
Klinkman, M.S., M.D., Ananda Sen, Ph.D., all of U-M. And Kurt Kroenke, M.D., of
Roudebush VA Medical Center and Indiana University. The research was partially
supported by a grant from Eli Lilly & Co., which did not have editorial control
over the content of the article. The Regents of the University of Michigan placed
the tool into the public domain. |